The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Flagged first, then by citations
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 501–600 of 1,002
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Gou, Q., Gou, Q., Gan, X., & Xie, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-61087-2 · Cited by 42
Genomic Alteration–Driven Clinical Trial Designs in Oncology
Simon, R. M. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2413 · Cited by 41
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma
Brown, N. F., Carter, T. J., & Mulholland, P. J. (2016) · CNS Oncology · doi:10.2217/cns-2016-0031 · Cited by 41
Váradi, Z., Bánusz, R., Csomor, J., Kállay, K. M., Varga, E., Kertész, G., & Csóka, M. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s121615 · Cited by 41
Cohn, A. L., Day, B.-M., Abhyankar, S. S., Mckenna, E. F., Riehl, T., & Puzanov, I. J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s120440 · Cited by 41
Self-citationMutation matters in precision medicine: A future to believe in
Dey, N., Williams, C. B., Leyland-Jones, B. R., & De, P. K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.002 · Cited by 41
BRAF Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition
Moujaber, T., Etemadmoghadam, D., Kennedy, C. J., Chiew, Y.-E., Balleine, R. L., Saunders, C. A. B., Wain, G., Gao, B., Hogg, R. J., Srirangan, S., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00221 · Cited by 41
Pemigatinib, a Potent Inhibitor of FGFRs for the Treatment of Cholangiocarcinoma
Merz, V., Zecchetto, C., & Melisi, D. (2020) · Future Oncology · doi:10.2217/fon-2020-0726 · Cited by 41
BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscape
Planchard, D., Sanborn, R. E., Negrao, M. V., Vaishnavi, A., & Smit, E. F. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00552-7 · Cited by 45
Role of Biologics in First-Line Treatment of Colorectal Cancer
Mahipal, A., & Grothey, A. F. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.018382 · Cited by 42
Cabanillas, M. E., Williams, M. D., Gunn, G. B., Weitzman, S. P., Burke, L., Busaidy, N. L., Ying, A. K., Yiin, Y. H., William, W. N., Lu, C. S., et al. (2017) · Head & Neck · doi:10.1002/hed.24784 · Cited by 40
New insights in lymphangioleiomyomatosis and pulmonary Langerhans cell histiocytosis
Torre, O., Elia, D., Caminati, A., & Harari, S. A. (2017) · European Respiratory Review · doi:10.1183/16000617.0042-2017 · Cited by 40
Molecular Targets in Non-Small Cell Lung Cancer.
Griffin, R. P., & Ramirez, R. A. (2017) · PubMed · Cited by 42
Simões‐Pereira, J., Capitão, R., Limbert, E., & Leite, V. A. P. H. (2019) · Cancers · doi:10.3390/cancers11081188 · Cited by 40
Advances in anti-BRAF therapies for lung cancer
Roviello, G., D’Angelo, A., Sirico, M., Pittacolo, M., Conter, F. U., & Sobhani, N. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01068-8 · Cited by 42
EGFR pathway targeting drugs in head and neck cancer in the era of immunotherapy
Kang, J. J., Ko, A., Kil, S. H., Clair, J. M., Shin, D. S., Wang, M. B., & Srivatsan, E. S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188827 · Cited by 45
Mutations in genes encoding PI3K‐AKT and MAPK signaling define anogenital papillary hidradenoma
Pfarr, N., Sinn, H., Klauschen, F., Flechtenmacher, C., Bockmayr, M. L., Ridinger, K., von Winterfeld, M., Warth, A., Lorenz, K., Budczies, J., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22315 · Cited by 39
Groisberg, R., Roszik, J., Conley, A. P., PATEL, S. R., & Subbiah, V. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0641-2 · Cited by 39
Self-citationSignature program: a platform of basket trials
Slosberg, E., Kang, B., Peguero, J., Taylor, M., Bauer, T., Berry, D., Braiteh, F., Spira, A., Meric-Bernstam, F., Stein, S., et al. (2018) · OncoTarget · doi:10.18632/oncotarget.25109 · Cited by 35
Voss, M. H., Chen, D., Reising, A., Marker, M., Shi, J., Xu, J., Ostrovnaya, I., Seshan, V., Redzematovic, A., Chen, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1833 · Cited by 39
Integrating Next-Generation Sequencing in the Clinical Pharmacogenomics Workflow
Giannopoulou, E., Κάτσιλα, Θ., Mitropoulou, C., Tsermpini, E. E., & Patrinos, G. P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00384 · Cited by 39
Waldschmidt, J. M., Kloeber, J. A., Anand, P., Frede, J., Kokkalis, A., Dimitrova, V., Potdar, S. V., Nair, M. S., Vijaykumar, T., Im, N. G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2040 · Cited by 38
Self-citationTargeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Odeniyide, P., Yohe, M. E., Pollard, K., Vaseva, A. V., Calizo, A., Zhang, L., Rodríguez, F. J., Gross, J. M., Allen, A. N., Wan, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02305-x · Cited by 38
Langerhans Cells—Revising Their Role in Skin Pathologies
Neagu, M. T., Constantin, C., Jugulete, G., Cauni, V. M., Dubrac, S., Szöllősi, A. G., & Zurac, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12122072 · Cited by 43
Califano, I., Smulever, A., Jerkovich, F., & Pitoia, F. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09833-1 · Cited by 38
Phosphoproteomics in translational research: a sarcoma perspective
Noujaim, J. C., Payne, L. S., Judson, I. R., Jones, R. L., & Huang, P. H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw030 · Cited by 38
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells
Vučković, S., Vandyke, K., Rickards, D. A., Winter, P. M., Brown, S. H. J., Mitchell, T. W., Liu, J., Lü, J., Askenase, P. W., Yuriev, E., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14561 · Cited by 38
Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement
Bayati, A. A., Plate, T., Bayati, M. J. A., Yan, Y., Lavi, E. S., & Rosenblatt, J. D. (2018) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2018.05.001 · Cited by 38
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Khaliq, M., & Fallahi‐Sichani, M. (2019) · Cancers · doi:10.3390/cancers11101480 · Cited by 39
Khaddour, K., Chicoine, M. R., Huang, J., Dahiya, S. M., & Ansstas, G. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7624 · Cited by 38
Manzi, J. L. L., Hoff, C. O., Ferreira, R., Pimentel, A., Datta, J., Livingstone, A. S., Vianna, R., & Abreu, P. (2023) · Cancers · doi:10.3390/cancers15113023 · Cited by 41
Cutting-Edge Therapies for Lung Cancer
La’ah, A. S., & Chiou, S. (2024) · Cells · doi:10.3390/cells13050436 · Cited by 36
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Rina, A., Maffeo, D., Minnai, F., Esposito, M., Palmieri, M., Serio, V. B., Rosati, D., Mari, F., Frullanti, E., & Colombo, F. (2024) · Cancers · doi:10.3390/cancers16162882 · Cited by 44
BRAF-Directed Therapy in Metastatic Colorectal Cancer
Korphaisarn, K., & Kopetz, S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000189 · Cited by 38
Targeted therapies in thyroid cancer: an extensive review of the literature
Bikas, A., Vachhani, S., Jensen, K. E., Vasko, V. V., & Burman, K. D. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1204230 · Cited by 37
An Update on Colorectal Cancer
Xue, L., Williamson, A. J., Gaines, S., Andolfi, C., Paul-Olson, T., Neerukonda, A. R., Steinhagen, E. F., Smith, R. K., Cannon, L. M., Polite, B. N., et al. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.02.003 · Cited by 39
Kaplan, H. G., Rostad, S. W., Ross, J. S., Ali, S. M., & Millis, S. Z. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7033 · Cited by 36
Raje, N. S., Chau, I., Hyman, D. M., Ribrag, V., Blay, J., Tabernero, J. M., Élez, E., Wolf, J., Yee, A. J., Kaiser, M., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00070 · Cited by 37
Self-citationPrecision Oncology in Sarcomas: Divide and Conquer
Pestana, R. C., Groisberg, R., Roszik, J., & Subbiah, V. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00247 · Cited by 36
Self-citationThe liquid biopsy in lung cancer
Ansari, J., Yun, J. W., Kompelli, A. R., Moufarrej, Y. E., Alexander, J. S., Herrera, G. A., & Shackelford, R. E. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.127 · Cited by 37
Current therapeutic approaches to diffuse grade II and III gliomas
Pïcca, A., Berzero, G., & Sanson, M. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617752039 · Cited by 39
Chakrabarti, S., Kamgar, M., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14112588 · Cited by 36
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation
Combe, P., Chauvenet, L., Frère‐Belda, M. L., Blons, H., Rousseau, C., Oudard, S. M., & Pujade-Lauraine, É. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0297-4 · Cited by 36
Konda, J. D., Olivero, M., Musiani, D., Lamba, S., & Renzo, M. F. D. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12042 · Cited by 36
Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
Groisberg, R., Hong, D. S., Roszik, J., Jankú, F., Tsimberidou, A. M., Javle, M. M., Meric‐Bernstam, F., & Subbiah, V. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1107 · Cited by 37
Self-citationWrzeszczyński, K. O., Felice, V., Abhyankar, A., Kozon, L., Geiger, H. M., Manaa, D., London, F., Robinson, D., Fang, X., Lin, Y.-T., et al. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.06.007 · Cited by 36
The Need for a Consensus Next‐generation Sequencing Panel for Mature Lymphoid Malignancies
Sujobert, P., Bris, Y. L., de Leval, L., Gros, A., Merlio, J. P., Pastoret, C., Huet, S., Sarkozy, C., Davi, F., Callanan, M. B., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000169 · Cited by 36
Drug resistance in targeted cancer therapies with RAF inhibitors
Degirmenci, U., Yap, J., Sim, Y. R. M., Qin, S., & Hu, J. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.36 · Cited by 36
Revolutionizing cancer drug development: Harnessing the potential of basket trials
Subbiah, V., Burris, H. A., & Kurzrock, R. (2023) · Cancer · doi:10.1002/cncr.35085 · Cited by 37
Self-citationShan, K. S., Rehman, T. U., Ivanov, S., Domingo, G. C., & Raez, L. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010624 · Cited by 42
P21‐activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells
Babagana, M., Johnson, S., Slabodkin, H., Bshara, W., Morrison, C., & Kandel, E. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22611 · Cited by 35
The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies
Lirov, R., Worden, F. P., & Cohen, M. S. (2017) · Drugs · doi:10.1007/s40265-017-0733-1 · Cited by 36
Goodman, A. M., Choi, M. P., Wieduwilt, M. J., Mulroney, C. M., Costello, C. L., Frampton, G. M., Miller, V. A., & Kurzrock, R. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00004 · Cited by 35
Hilal, T., Nakazawa, M., Hodskins, J., Villano, J. L., Mathew, A., Goel, G., Wagner, L. M., Arnold, S. M., DeSimone, P. A., Anthony, L. B., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3587-8 · Cited by 35
Faehling, M., Schwenk, B., Kramberg, S., Eckert, R., Volckmar, A., Stenzinger, A., & Sträter, J. (2017) · Oncotarget · doi:10.18632/oncotarget.20857 · Cited by 35
Ophthalmic Findings of Rosai-Dorfman Disease
Choi, M. B., Salomão, D. R., Smith, W. M., Pulido, J. S., & Garrity, J. A. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.01.037 · Cited by 35
Molecular screening to select therapy for advanced cancer?
Tannock, I. F., & Hickman, J. A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz088 · Cited by 35
Master protocols in clinical trials: a universal Swiss Army knife?
Sudhop, T., Brun, N. C., Riedel, C., Rosso, A., Broich, K., & Senderovitz, T. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30271-2 · Cited by 35
Remón, J., García‐Campelo, R., de Álava, E., Vera, R., Rodríguez‐Peralto, J. L., Rodríguez-Lescure, Á., Bellosillo, B., Garrido, P., Rojo, F., & Álvarez-Alegret, R. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02211-x · Cited by 37
Lamping, M., Benary, M., Leyvraz, S., Messerschmidt, C., Blanc, E., Kessler, T., Schütte, M., Lenze, D., Jöhrens, K., Burock, S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2019.12.017 · Cited by 35
RoBoT: a robust Bayesian hypothesis testing method for basket trials
Zhou, T., & Ji, Y. (2020) · Biostatistics · doi:10.1093/biostatistics/kxaa005 · Cited by 35
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges
Rizzo, A., Federico, A. D., Ricci, A. D., Frega, G., Palloni, A., Pagani, R., Tavolari, S., Marco, M. D., & Brandi, G. (2020) · Cancer Control · doi:10.1177/1073274820983013 · Cited by 34
Non-small-cell lung cancer: how to manage BRAF-mutated disease
Guaitoli, G., Zullo, L., Tiseo, M., Dankner, M., Rose, A. A. N., & Facchinetti, F. (2023) · Drugs in Context · doi:10.7573/dic.2022-11-3 · Cited by 35
Sugitani, I., Kiyota, N., Ito, Y., Onoda, N., Hiromasa, T., Horiuchi, K., Kinuya, S., Kondo, T., Moritani, S., Sugino, K., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0644 · Cited by 44
Gobbini, É., Galetta, D., Tiseo, M., Graziano, P., Rossi, A., Bria, E., Maïo, M. D., Rossi, G., Gregorc, V., Riccardi, F., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.06.009 · Cited by 34
Definitions and statistical properties of master protocols for personalized medicine in oncology
Renfro, L. A., & Mandrekar, S. J. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1372778 · Cited by 36
Gianì, F., Russo, G. L., Pennisi, M. A., Sciacca, L., Frasca, F., & Pappalardo, F. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty969 · Cited by 34
Salivary gland tumors: Molecular characterization and therapeutic advances for metastatic disease
Schvartsman, G., Pinto, N. A., Bell, D., & Ferrarotto, R. (2018) · Head & Neck · doi:10.1002/hed.25468 · Cited by 34
Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma
Saeed, A., Park, R., Al‐Jumayli, M., Al-Rajabi, R. M. T., & Sun, W. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.02.005 · Cited by 34
Cancer Treatment in the Genomic Era
Doherty, G. J., Petruzzelli, M., Beddowes, E. J., Ahmad, S. S., Caldas, C., & Gilbertson, R. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011840 · Cited by 36
Crespo-Rodriguez, E., Bergerhoff, K. F., Bozhanova, G., Foo, S., Patin, E. C., Whittock, H., Buus, R., Haider, S. A., Muirhead, G., Thway, K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000698 · Cited by 34
Pathway-Directed Therapy in Multiple Myeloma
John, L., Krauth, M. T., Podar, K., & Raab, M. (2021) · Cancers · doi:10.3390/cancers13071668 · Cited by 33
Horak, P., Leichsenring, J., Goldschmid, H., Kreutzfeldt, S., Kazdal, D. N., Teleanu, V., Endris, V., Gieldon, L., Allgäuer, M., Volckmar, A., et al. (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22987 · Cited by 34
KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders
Vendramini, E., Bomben, R., Pozzo, F., Bittolo, T., Tissino, E., Gattei, V., & Zucchetto, A. (2022) · Cancers · doi:10.3390/cancers14030666 · Cited by 37
Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management
Yuan, J., & Guo, Y. (2022) · Cancers · doi:10.3390/cancers15010179 · Cited by 33
Mourah, S., Lorillon, G., Meignin, V., Vercellino, L., de Margerie‐Mellon, C., Pagès, C., Goldwirt, L., How‐Kit, A., Tost, J., Lebbé, C., et al. (2015) · Blood · doi:10.1182/blood-2015-06-650036 · Cited by 33
BRAF inhibitors in metastatic non-small cell lung cancer
Anguera, G., & Majem, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.129 · Cited by 33
Update on systemic therapy for colorectal cancer: biologics take sides
Gbolahan, O. B., & O’Neil, B. H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.01.12 · Cited by 33
Basket Trials for Intractable Cancer
Qin, B., Jiao, X., Liu, K., Wu, Y., He, X., Liu, J., Qin, W., Wang, Z., & Zang, Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00229 · Cited by 33
Basket Designs: Statistical Considerations for Oncology Trials
Kaizer, A. M., Koopmeiners, J. S., Kane, M. J., Roychoudhury, S., Hong, D. S., & Hobbs, B. P. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00194 · Cited by 35
Mu, Y., Yang, K., Hao, X., Wang, Y., Wang, L., Liu, Y., Lin, L., Li, J., & Xing, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00603 · Cited by 34
Adult pilocytic astrocytoma in the molecular era: a comprehensive review
Gregory, T. A., Chumbley, L. B., Henson, J. W., & Theeler, B. J. (2021) · CNS Oncology · doi:10.2217/cns-2020-0027 · Cited by 33
Autophagy Inhibition in BRAF-Driven Cancers
Foth, M., & McMahon, M. (2021) · Cancers · doi:10.3390/cancers13143498 · Cited by 33
Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis
Ding, Y., Jiang, J., Xu, J., Chen, Y., Zheng, Y., Jiang, W., Mao, C., Jiang, H., Bao, X., Shen, Y., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100407 · Cited by 34
Guo, W., Du, K., Luo, S., & Hu, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.861959 · Cited by 34
Osmanbeyoglu, H. U., Toska, E., Chan, C., Baselga, J. M., & Leslie, C. S. (2017) · Nature Communications · doi:10.1038/ncomms14249 · Cited by 37
Self-citationImplementing precision cancer medicine in the genomic era
Chen, H., Bonneville, R., & Roychowdhury, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.009 · Cited by 34
Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35
Bielamowicz, K., Dimitrion, P. M., Abla, O., Bomken, S. N., Campbell, P. K., Collin, M. P., Degar, B. A., Diamond, E. L., Eckstein, O. S., El‐Mallawany, N. K., et al. (2024) · Cancer · doi:10.1002/cncr.35301 · Cited by 32
Self-citationGrowth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells
Kurata, K., Onoda, N., Noda, S., Kashiwagi, S., Asano, Y., Hirakawa, K., & Ohira, M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3723 · Cited by 32
Cancer Precision Medicine: Why More Is More and DNA Is Not Enough
Schütte, M., Ogilvie, L. A., Rieke, D. T., Lange, B. M. H., Yaspo, M., & Lehrach, H. (2017) · Public Health Genomics · doi:10.1159/000477157 · Cited by 30
Schmoll, H., Arnold, D., de Gramont, A., Ducreux, M. P., Grothey, A. F., O'Dwyer, P. J., Cutsem, E. V., Hermann, F., Bosanac, I., Bendahmane, B., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2632-6 · Cited by 32
Self-citationHeterogeneity and phenotypic stratification in acute respiratory distress syndrome
Lawler, P. R., & Fan, E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30287-x · Cited by 32
Cardiovascular manifestations of Erdheim–Chester disease
Ghotra, A. S., Thompson, K., Lopez‐Mattei, J., Bawa, D., Hernández, R., Banchs, J. A., Palaskas, N. L., Iliescu, C., Kim, P. Y., Yusuf, S. W., et al. (2018) · Echocardiography · doi:10.1111/echo.14231 · Cited by 32
Mutational interactions define novel cancer subgroups
Kuipers, J., Thurnherr, T., Moffa, G., Suter, P., Behr, J., Goosen, R., Christofori, G., & Beerenwinkel, N. (2018) · Nature Communications · doi:10.1038/s41467-018-06867-x · Cited by 31
Liquid biopsies for multiple myeloma in a time of precision medicine
Ferreira, B. V., Caetano, J., Barahona, F., Lopes, R., Carneiro, E. A., Costa‐Silva, B., & Joao, C. M. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01897-9 · Cited by 36
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 32
Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy
Wang, S. J., Li, R., Ng, T. S. C., Luthria, G., Oudin, M. J., Prytyskach, M., Köhler, R. H., Weissleder, R., Lauffenburger, D. A., & Miller, M. A. (2020) · Science Advances · doi:10.1126/sciadv.aaz8521 · Cited by 32
Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J. M., Macarulla, T. M., & Arribas, J. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4263 · Cited by 32
Self-citationBRAF Inhibitors in Non-Small Cell Lung Cancer
Sforza, V., Palumbo, G., Cascetta, P., Carillio, G., Manzo, A., Montanino, A., Sandomenico, C., Costanzo, R., Esposito, G., Laudato, F., et al. (2022) · Cancers · doi:10.3390/cancers14194863 · Cited by 34
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
